We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Use of proton pump inhibitors in hematopoietic stem cell transplantation does not increase the frequency of febrile neutropenia.
- Authors
OZKAN, M. C.; DONMEZ, A.; ARSLAN, A.; AYDEMIR, S.; TOMBULOGLU, M.
- Abstract
OBJECTIVE: Despite the fact that proton pump inhibitor (PPI) use is a risk factor for infections in heterogeneous groups of patients, there are only a limited data related to PPI use and febrile neutropenic episodes (FNEs) in hematopoietic stem cell transplantation (HSCT) patients. PATIENTS AND METHODS: In a 7-year period, we retrospectively reviewed 145 HSCT data to identify a risk factor for PPI use for febrile neutropenia. The follow-up process of 125 (86.2%) of the HSCTs was complicated with FNEs. RESULTS: A multivariate analysis indicated that PPI use was not significantly associated with FNEs (Odds ratio [OR]: 0.46; 95% Confidence Interval [CI] 0.12-2.16; p = 0.24) or bacterial culture positivity (OR: 1.37; 95% CI 0.45-4.18; p = 0.58). CONCLUSIONS: Our study revealed that PPI use does not appear to be a risk factor for FNE or bacterial culture positivity for HSCT patients but further studies are needed.
- Subjects
PROTON pump inhibitors; ENZYME inhibitors; HEMATOPOIETIC stem cell transplantation; FEBRILE neutropenia; DISEASE complications; DISEASE risk factors
- Publication
European Review for Medical & Pharmacological Sciences, 2015, Vol 19, Issue 21, p4105
- ISSN
1128-3602
- Publication type
Article